

Current Data Parameters
NAME N_Dualmalyds
EXPNO 2
PROCNO 1
F1 - Acquisition Parameters
Date_ 500050
Time 18.23
INSTRUM spect300
PROBHD 5 mm Dual 13
PULPROG zg
TD 32768
SOLVENT CDCl3
NS 16
DS 2
SWH 4708.698 Hz
FIDRES 0.143683 Hz
AQ 3.4803117 sec
RG 32
DW 106.269 usec
DE 114.29 usec
TE 300.0 K
D1 2.00000003 sec
P1 10.65 usec
DEC 114.29 usec
SFO1 300.1318902 MHz
NUC1 1H
PL1 -5.00 dB
F2 - Processing parameters
SI 16384
SF 300.1300251 MHz
WDW EM
SSB 0
LB 0.00 Hz
GB 0
PC 1.00
1D NMR plot parameters
CX 20.00 cm
F1P 10.715 ppm
F1 1040.84 Hz
F2P -5.252 ppm
F2 -375.70 Hz
PPMCM 0.69230 ppm/cm
HZCM 193.78716 Hz/cm
0.0220
0.0183
0.0001
0.0110
1.4268
1.5292
2.0038
2.3082
3.6128
3.6268
3.6433
3.6557
3.6616
3.6659
3.6803
3.6939
3.7169
3.7236
3.9860
6.2811
7.2654
7.2776
3.7979
0.4250
0.7354
3.6383
0.6226
0.3822
1.7377
0.9032
ppm
Integral

Fig-1




Fig-1: ^{13}C NMR spectrum of the polymer of the present invention




Fig-3: Fourier Transform Infrared (FT-IR) spectrum of the polymer of the present invention.

Fig-4: TGA thermogram of the polymer of the present invention





Fig-5: DSC thermogram of the polymer of the present invention







Fig-6: Pharmacokinetic blood profile of 14C-Labeled polymer of the present invention

Fig-7: Photographs of S&E Stained Rabbit ear lobe site after 48 hour of the subcutaneous injection of a 10% Dextrose solution (Control)








Fig-8: ~~Photographs of S&E Stained Rabbit ear lobe site after 48 hour of the subcutaneous injection of an aqueous solution of Polymer of the present invention~~









Fig-9: ~~Photographs of S&E Stained Rabbit's Marginal Ear Vein site after 24 hour of Intravenous Injection of a 10% Dextrose solution (Control)~~










Fig-10: ~~Photographs of S&E Stained Rabbit's Marginal Ear Vein site after 24 hour of Intravenous Injection of an aqueous solution of Polymer of the present invention~~




Fig-11: ~~A Typical Method For Preparation and Administration to patients in need thereof of the Nanoparticulate Pharmaceutical Composition of the Present Invention~~

